Ocean Biomedical issued patent for bispecific cancer immunotherapy treatment

Ocean Biomedical announced that a new, broad U.S. patent for bispecific antibodies targeting chitinase 3-like-1 and programmed cell death protein 1, a promising new approach that has emerged from prior breakthrough discoveries that CHi3L1 is a “master regulator” of tumor growth in multiple visceral cancers, has been issued to one of its Scientific Co-founders, Dr. Jack A. Elias, MD. Ocean Biomedical’s bispecific antibody is a immunotherapy approach that demonstrates promising synergy by combining Ocean’s proprietary anti-CHi3L1 antibody with existing immune checkpoint inhibitors that target PD-1 in a bispecific-antibody format. As seen in the image below, these bispecific antibodies have been shown to synergistically kill tumor cells at levels dramatically exceeding the effectiveness of either the anti-CHi3L1 antibody or the anti-PD-1 antibody alone-in multiple cancer types and multiple animal models. Ocean Biomedical’s breakthrough comes at a critical time for the evolving immuno-oncology sector, which is working to realize the promise of immune checkpoint inhibition. Current challenges include the limited number of cancer patients demonstrating initial responses and the significant number of responders relapsing following classic immune checkpoint blockade. Ocean Biomedical’s new approach combines Ocean’s anti-CHi3L1 antibody with classic immune checkpoint blockade, and the initial magnitude and duration of response from Ocean’s bispecific immunotherapy treatment in multiple animal models of visceral cancer was synergistically enhanced compared to immune checkpoint blockade alone. The new bispecific patent has been granted for prostate cancer, colon cancer, rectal cancer, ovarian cancer, kidney cancer, breast cancer, glioblastoma, melanoma, and lung cancer. The newest claims dovetail with and fortify recently issued patents with claims coverage focused on composition of matter of monoclonal antibodies targeting and inhibiting CHi3L1.